Boehringer Ingelheim inks third collab in four years with Danish biotech company
Another deal has fallen into place between Boehringer Ingelheim and the Danish biotech and contract research firm Gubra. The parties have entered into lucrative deals in the past, but will not disclose the financial terms underlying the new agreement.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
Danish biotech and contract research firm Gubra has signed a new agreement with German pharmaceutical giant Boehringer Ingelheim on the development of peptide compounds for treating obesity, according to a joint press announcement from the companies.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme recruits new CEO
For subscribers
Biomarin awaits crucial approvals and flat growth in 2021
For subscribers
